Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2011

View Archived Issues

Studies assess 2-year and sustained-release ONO-5334 therapy

Merck & Co. assesses new agents potentiating beta-lactam antibiotics against MRSA

New serotonin 5-HT3 receptor partial agonists developed for irritable bowel syndrome

Kancera products show activity against pancreatic cancer cells

Vernalis and Servier reach milestone in oncology collaboration

Nanotherapeutics receives U.S. government contract to develop oral radiation drug

Threshold Pharmaceuticals begins pivotal study of TH-302

Pfizer reports topline phase III data on combination therapy for invasive aspergillosis

BIO-11006 is efficacious in phase IIa trial

AstraZeneca presents novel DNA gyrase inhibitors

New TTK inhibitors synthesized by Bayer Schering Pharma

Chinese institute discloses novel angiotensin AT1 receptor antagonists

Orexo presents novel phosphodiesterase 4 inhibitors

Roche patents new TYK2 inhibitors

Novel chemokine CCR2 receptor antagonists prepared by AstraZeneca

Second phase IIb trial of ALKS-37 begins for opioid-induced constipation

Phase IIb trial of SB-509 does not meet primary or secondary endpoints

Xoma's botulism program receives support from NIAID

Pfizer launches BeneFIX RTS in Europe

Phase III study of Cx-601 receives financial support

EMA accepts MAA for IB-1001

MedImmune in-licenses tremelimumab from Pfizer

Enrollment completed in GeoVax's HIV/AIDS vaccine study

Array BioPharma reports results from selumetinib NSCLC study

Update on Adventrx's NDA for Exelbine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...